XML 42 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Cash flows from operating activities:    
Net income (loss) $ (1,848) $ (917)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Provision for doubtful accounts 742 244
Depreciation and amortization 9,427 6,674
Deferred income taxes (45) (1,249)
Gain (Loss) on Disposition of Property Plant Equipment 38 0
(Gain) Loss on Interest Rate Swaps 0 (82)
Compensation expense related to stock-based awards and employee stock purchase plan 2,832 2,827
Foreign Currency Transaction Gain (Loss), Unrealized 191 0
Changes in operating assets and liabilities:    
Accounts receivable 644 481
Inventories (3,807) (2,327)
Prepaid expenses and other assets (2,282) (528)
Other non-current assets 1,043 496
Accounts payable (2,145) 3,315
Deferred revenue 355 1,285
Accrued expenses and other current liabilities 5,602 610
Other long-term liabilities (96) (170)
Net cash provided by operating activities 10,651 10,659
Cash flows from investing activities:    
Capital expenditures (4,881) (3,535)
Payments to Acquire Businesses, Net of Cash Acquired 0 45,165
Purchases of marketable securities (13,807) (10,618)
Maturities and sales of marketable securities 11,719 32,529
Net cash used in investing activities (6,969) (26,789)
Cash flows from financing activities:    
Repayments of long-term debt (980) (951)
Repayments of Long-term loan (3,656) (1,219)
Proceeds from Long-term loan 0 65,000
Repayments of Long-term Lines of Credit 0 (30,000)
Payments of employee restricted stock withholdings 345 482
Proceeds From Stock Options Exercised and Employee Stock Purchase Plan 260 572
Net cash (used in) provided by financing activities (4,721) 32,920
Effect of exchange rate changes on cash and cash equivalents (627) (225)
Net (decrease) increase in cash and cash equivalents (1,666) 16,565
Cash and cash equivalents at beginning of period 25,289 9,358
Cash and cash equivalents at end of period $ 23,623 $ 25,923